Therapeutic targeting of casein kinase 1δ in breast cancer

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Science Translational Medicine

• Publication date

  2015-12-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1126/scitranslmed.aac8773PMID 26676609PMCID PMC4809734
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer statistics, 2014

  2014cited by this paper
• The CK1 Family: Contribution to Cellular Stress Response and Its Role in Carcinogenesis

  2014cited by this paper
• A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models.

  2013cited by this paper
• Development of highly selective casein kinase 1δ/1ε (CK1δ/ε) inhibitors with potent antiproliferative properties.

  2013influential reference
• Molecular Oncology: Targeted therapies in breast cancer

  2013cited by this paper
• Comprehensive molecular portraits of human breast tumours

  2013cited by this paper
• WNT10B/β-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer

  2013cited by this paper
• Myc is required for β-catenin-mediated mammary stem cell amplification and tumorigenesis

  2013cited by this paper
• β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression.

  2013cited by this paper
• The planar cell polarity pathway drives pathogenesis of chronic lymphocytic leukemia by the regulation of B-lymphocyte migration.

  2013cited by this paper
• WNT 10 B / β-catenin Signaling Induces HMGA 2 and Proliferation in Metastatic Triple-Negative Breast Cancer

  2012cited by this paper
• Wnt signaling in cancer.

  2012cited by this paper
• Expression of Dickkopf-1 and Beta-Catenin Related to the Prognosis of Breast Cancer Patients with Triple Negative Phenotype

  2012cited by this paper
• Trastuzumab containing regimens for early breast cancer.

  2012cited by this paper
• Casein kinase I epsilon interacts with mitochondrial proteins for the growth and survival of human ovarian cancer cells

  2012cited by this paper
• Impaired CK1 Delta Activity Attenuates SV40-Induced Cellular Transformation In Vitro and Mouse Mammary Carcinogenesis In Vivo

  2012cited by this paper
• Comprehensive molecular portraits of human breast tumors

  2012cited by this paper
• Targeted therapies for breast cancer.

  2011cited by this paper
• β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation

  2011cited by this paper
• IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1δ/ɛ and Wnt/β-catenin independent inhibition of mitotic spindle formation

  2011cited by this paper
• Casein kinase 1: Complexity in the family.

  2011cited by this paper
• GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers

  2011cited by this paper
• Molecular stratification of triple-negative breast cancers.

  2011cited by this paper
• Breast cancer prognostic classification in the molecular era: the role of histological grade

  2010cited by this paper
• Notch Signaling Pathway as a Therapeutic Target in Breast Cancer

  2010cited by this paper
• Breast cancer-specific mutations in CK1ε inhibit Wnt/β-catenin and activate the Wnt/Rac1/JNK and NFAT pathways to decrease cell adhesion and promote cell migration

  2010cited by this paper
• CK1ε Is Required for Breast Cancers Dependent on β-Catenin Activity

  2010cited by this paper
• Triple-negative breast cancer: disease entity or title of convenience?

  2010cited by this paper
• Molecular stratification of triple-negative breast cancers.

  2010cited by this paper
• Lentiviral Vectors to Probe and Manipulate the Wnt Signaling Pathway

  2010cited by this paper
• Supervised risk predictor of breast cancer based on intrinsic subtypes.

  2009cited by this paper
• Single-vector inducible lentiviral RNAi system for oncology target validation

  2009cited by this paper
• Anti-apoptotic and growth-stimulatory functions of CK1 delta and epsilon in ductal adenocarcinoma of the pancreas are inhibited by IC261 in vitro and in vivo

  2008cited by this paper
• Wnt-3a utilizes a novel low dose and rapid pathway that does not require casein kinase 1-mediated phosphorylation of Dvl to activate beta-catenin.

  2007cited by this paper
• Disease-associated casein kinase I delta mutation may promote adenomatous polyps formation via a Wnt/beta-catenin independent mechanism.

  2007cited by this paper
• A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells.

  2006cited by this paper
• Gene expression signatures of morphologically normal breast tissue identify basal-like tumors

  2006cited by this paper
• Disease‐associated casein kinase I δ mutation may promote adenomatous polyps formation via a Wnt/β‐catenin independent mechanism

  2006cited by this paper
• Wnt-dependent Regulation of the E-cadherin Repressor Snail*

  2005cited by this paper
• 1–40 Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period

  2005cited by this paper
• An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells.

  2004cited by this paper
• Wnt Proteins in Mammary Development and Cancer

  2004cited by this paper
• Breast cancer with synchronous metastases: trends in survival during a 14-year period.

  2004cited by this paper
• Control of -Catenin Phosphorylation/Degradation by a Dual-Kinase Mechanism

  2002cited by this paper
• Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism.

  2002cited by this paper
• Wnt signaling in breast cancer: have we come full circle?

  2001cited by this paper
• b-Catenin , a novel prognostic marker for breast cancer : Its roles in cyclin D 1 expression and cancer progression

  2000cited by this paper
• Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression.

  2000cited by this paper

• Dysfunctional circadian-driven dynamics in gut microbiota and tumor microenvironment

  2025cites this paper
• CK1ε/SRSF10 axis regulates the alternative splicing of Bcl-x in lung cancer cells

  2025cites this paper
• Integrated proteome, phospho-proteome and malonyl-proteome revealed a molecular alteration of breast cancer

  2025cites this paper
• CSNK1D inhibition suppresses head and neck squamous cell carcinoma progression through SHH and PTCH1 pathway

  2025cites this paper
• Pharmacological targeting of casein kinase 1δ suppresses oncogenic NRAS-driven melanoma

  2024cites this paper
• Targeting CK1δ and CK1ε as a New Therapeutic Approach for Clear Cell Renal Cell Carcinoma

  2024influential citation
• Tumour-specific phosphorylation of serine 419 drives alpha-enolase (ENO1) nuclear export in triple negative breast cancer progression

  2024cites this paper
• The Relationship between Circadian Rhythm and Cancer Disease

  2024cites this paper
• Identification of CSNK1D and KLK6 as two common upregulated genes present in BRCA1 mutated triple-negative breast cancer and ovarian epithelial carcinoma

  2024cites this paper
• Proteome‐based molecular subtyping and therapeutic target prediction in gastric cancer

  2024cites this paper
• Adenine derivatives as inhibitors of the casein kinase CK1delta enzyme

  2024cites this paper
• The CK1ε/SIAH1 axis regulates AXIN1 stability in colorectal cancer cells

  2024cites this paper
• Isoform-specific C-terminal phosphorylation drives autoinhibition of Casein Kinase 1

  2024cites this paper
• Protein kinase inhibitors in the management of cancer: therapeutic opportunities from natural compounds

  2024cites this paper
• Targeting Wnt Pathways with Small Molecules as New Approach in Cardiovascular Disease

  2024cites this paper
• siRNA-based strategies to combat drug resistance in gastric cancer

  2024cites this paper
• Casein Kinase 1α—A Target for Prostate Cancer Therapy?

  2024cites this paper
• Targeting casein kinase 1 for cancer therapy: current strategies and future perspectives

  2023cites this paper
• CK1δ and CK1ε Signaling Sustains Mitochondrial Metabolism and Cell Survival in Multiple Myeloma

  2023cites this paper
• Prognostic value and immunological role of CSNK1D in human cancers

  2023cites this paper
• The role of circadian rhythm in breast cancer, lung cancer, and colorectal cancer

  2023cites this paper
• DNA replication stress stratifies prognosis and enables exploitable therapeutic vulnerabilities of HBV-associated hepatocellular carcinoma: An in-silico precision oncology strategy

  2023cites this paper
• Structure-Based Development of Isoform-Selective Inhibitors of Casein Kinase 1ε vs Casein Kinase 1δ.

  2023cites this paper
• “Dual Anta-Inhibitors” of the A2A Adenosine Receptor and Casein Kinase CK1delta: Synthesis, Biological Evaluation, and Molecular Modeling Studies

  2023cites this paper
• Casein Kinase 1 and Human Disease: Insights From the Circadian Phosphoswitch

  2022cites this paper
• Circadian disruption: from mouse models to molecular mechanisms and cancer therapeutic targets

  2022cites this paper
• Circadian gene CSNK1D promoted the progression of hepatocellular carcinoma by activating Wnt/β-catenin pathway via stabilizing Dishevelled Segment Polarity Protein 3

  2022cites this paper
• Casein kinase 1α mediates eryptosis: a review

  2022cites this paper
• CSNK1D is associated with stemness and invasiveness in glioblastoma.

  2022cites this paper
• Inhibition of casein kinase 1δ disrupts translation initiation and exerts potent antilymphoma activity

  2022cites this paper
• CK1 Is a Druggable Regulator of Microtubule Dynamics and Microtubule-Associated Processes

  2022cites this paper
• Circadian rhythms and cancers: the intrinsic links and therapeutic potentials

  2022cites this paper
• Casein Kinase 1δ Inhibitors as Promising Therapeutic Agents for Neurodegenerative Disorders.

  2022cites this paper
• Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.

  2022cites this paper
• Stress-activated kinases as therapeutic targets in pancreatic cancer

  2021cites this paper
• RETRACTED ARTICLE: β-Trcp and CK1δ-mediated degradation of LZTS2 activates PI3K/AKT signaling to drive tumorigenesis and metastasis in hepatocellular carcinoma

  2021cites this paper
• Time to fight: targeting the circadian clock molecular machinery in cancer therapy.

  2021cites this paper
• Developing novel classes of protein kinase CK1δ inhibitors by fusing [1,2,4]triazole with different bicyclic heteroaromatic systems.

  2021cites this paper
• Small-Molecule Inhibitors Targeting the Canonical WNT Signaling Pathway for the Treatment of Cancer.

  2021cites this paper
• Clocking cancer: the circadian clock as a target in cancer therapy

  2021cites this paper
• Discovery of an Orally Bioavailable Small-Molecule Inhibitor for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.

  2021cites this paper
• Casein Kinase 1D Encodes a Novel Drug Target in Hedgehog—GLI-Driven Cancers and Tumor-Initiating Cells Resistant to SMO Inhibition

  2021cites this paper
• The Wnt signaling pathway in tumorigenesis, pharmacological targets, and drug development for cancer therapy

  2021cites this paper
• DNA replication stress stratifies prognosis and enables exploitable therapeutic vulnerabilities of HBV-associated hepatocellular carcinoma: an in silico strategy towards precision oncology

  2021cites this paper
• Controversial roles of cold‑inducible RNA‑binding protein in human cancer (Review).

  2021cites this paper
• Systematic analyses of the role of prognostic and immunological EIF3A, a reader protein, in clear cell renal cell carcinoma

  2021cites this paper
• mRNA alternative polyadenylation (APA) in regulation of gene expression and diseases.

  2021cites this paper
• Overcoming Fungal Echinocandin Resistance through Inhibition of the Non-essential Stress Kinase Yck2.

  2020cites this paper
• Targeting Casein Kinase 1 (CK1) in Hematological Cancers

  2020cites this paper
• Identification of potential gene drivers of cutaneous squamous cell carcinoma

  2020cites this paper
• A novel targeted delivery system for drug-resistant hepatocellular carcinoma therapy.

  2020cites this paper
• Identification and characterization of mammaglobin-A epitope in heterogenous breast cancers for enhancing tumor-targeting therapy

  2020cites this paper
• Effects of CK1 specific inhibitors on wild type and mutant CK1δ in vitro and their ability to inhibit growth of tumor cell lines

  2020cites this paper
• An approach using Caenorhabditis elegans screening novel targets to suppress tumour cell proliferation

  2020cites this paper
• Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase

  2020cites this paper
• CK1δ as a potential therapeutic target to treat bladder cancer

  2020influential citation
• CK1 Delta Is an mRNA Cap-Associated Protein That Drives Translation Initiation and Tumor Growth

  2020cites this paper
• Synthesis and evaluation of novel 7H-pyrrolo-[2,3-d]pyrimidine derivatives as potential anticancer agents.

  2019cites this paper
• Longdaysin inhibits Wnt/β-catenin signaling and exhibits antitumor activity against breast cancer

  2019cites this paper
• Casein Kinase 1 Delta Regulates Cell Proliferation, Response to Chemotherapy and Migration in Human Ovarian Cancer Cells

  2019influential citation
• Facts and myths of selective casein kinase 1 ε inhibition

  2019cites this paper
• Interplay between Circadian Clock and Cancer: New Frontiers for Cancer Treatment.

  2019cites this paper
• Structure, regulation, and (patho-)physiological functions of the stress-induced protein kinase CK1 delta (CSNK1D).

  2019cites this paper
• Time will tell: Circadian clock dysregulation in triple negative breast cancer.

  2019cites this paper
• WNT Signaling in Cardiac and Vascular Disease

  2018cites this paper
• Oocyte DNA damage quality control requires consecutive interplay of CHK2 and CK1 to activate p63

  2018cites this paper
• Ribosome biogenesis factor Ltv1 chaperones the assembly of the small subunit head

  2018influential citation
• Silencing of casein kinase 1 delta reduces migration and metastasis of triple negative breast cancer cells

  2018influential citation
• Tumor promoter TPA activates Wnt/β-catenin signaling in a casein kinase 1-dependent manner

  2018cites this paper
• Potential signaling pathways as therapeutic targets for overcoming chemoresistance in mucinous ovarian cancer.

  2018cites this paper
• Comprehensive Characterization of Alternative Polyadenylation in Human Cancer.

  2018cites this paper
• Optimized 4,5-Diarylimidazoles as Potent/Selective Inhibitors of Protein Kinase CK1δ and Their Structural Relation to p38α MAPK

  2017cites this paper
• Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature

  2017cites this paper
• Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer.

  2017cites this paper
• CK1δ: an exploitable vulnerability in breast cancer.

  2016cites this paper
• Design, Synthesis, and Optimization of CK1δ Inhibitors

  2016cites this paper
• Hrr25/CK1δ-directed release of Ltv1 from pre-40S ribosomes is necessary for ribosome assembly and cell growth

  2015cites this paper